Intrapleural Immunotherapy

Intrapleural Immunotherapy for Mesothelioma: Locoregional Delivery, Oncolytic Viruses, and 2 Active Trials (2026)

Intrapleural Immunotherapy Quick Facts
Delivering immune-activating treatment directly into the chest cavity for pleural mesothelioma
What It Is	Immunotherapy given locally into the pleural space, not through a vein
Approaches in Trials	Oncolytic viruses; intrapleural photodynamic therapy plus anti-PD-1
Rationale	Concentrate treatment at the tumor; provoke a local immune response
Active Trials	NCT06031636 (Recruiting); NCT04400539 / IMPALA (Recruiting, Phase 2)
Related	Mesothelin CAR-T (cell therapy, delivered separately)
Status	Investigational — not FDA-cleared

Executive Summary

Intrapleural immunotherapy is an investigational strategy that delivers immune-activating treatment directly into the pleural space — the thin cavity between the lung and chest wall where pleural mesothelioma grows — rather than through a vein. The idea is to concentrate treatment where the tumor lives and to provoke a strong local immune response with fewer whole-body side effects. Two locoregional approaches are being tested in patients: oncolytic viruses, which are engineered to infect and kill cancer cells while alerting the immune system, and intrapleural photodynamic therapy combined with anti-PD-1 immunotherapy. A registration study is evaluating an oncolytic adenovirus (H101) plus a PD-1 inhibitor (NCT06031636, Recruiting), and the IMPALA pilot trial is testing intrapleural photodynamic therapy followed by nivolumab (NCT04400539, Recruiting, Phase 2). Intrapleural immunotherapy is distinct from mesothelin-directed CAR-T cell therapy, which is covered separately. All of these approaches are investigational and none is FDA-cleared for mesothelioma.

Why This Matters

Pleural mesothelioma has a feature that most cancers do not: the tumor lines an accessible body cavity that doctors can reach directly, through a chest tube or keyhole thoracic surgery. That accessibility makes the pleural space an appealing target for delivering treatment locally. For patients whose disease has not responded fully to standard systemic therapy, locoregional immunotherapy represents one of the more novel research directions — and understanding what is genuinely in trials, versus what is still preclinical, helps families evaluate options realistically.

---

At a Glance

Intrapleural immunotherapy for pleural mesothelioma in 2026:

• What it is — immune-activating treatment delivered directly into the pleural cavity rather than intravenously, to concentrate the effect at the tumor.
• Why it is being studied — systemic immunotherapy helps many patients but resistance is common, motivating locoregional strategies that may stimulate a stronger local immune response.
• Oncolytic viruses — engineered viruses that infect and kill cancer cells while triggering immune recognition; an oncolytic adenovirus (H101) plus a PD-1 inhibitor is under study in a recruiting registration trial.
• Intrapleural photodynamic therapy — the IMPALA pilot trial delivers photodynamic therapy into the pleural space by video-assisted thoracoscopy, followed by the anti-PD-1 drug nivolumab.
• Delivery mechanics — reproducible intrapleural delivery is an active preclinical research area, with refined injection techniques developed in laboratory models.
• Distinct from cell therapy — locoregional CAR-T cell therapy also uses the pleural route but is a separate modality covered on its own page.
• Both trials recruiting — NCT06031636 and NCT04400539 are listed as Recruiting; no locoregional immunotherapy is yet an approved standard.
• Investigational — intrapleural immunotherapy is not FDA-cleared for mesothelioma; it is available only within clinical trials.

---

Key Facts

Essential Intrapleural Immunotherapy Information
What Is Delivered	Oncolytic viruses or photodynamic therapy plus anti-PD-1, given into the pleural space
Route	Intrapleural (chest tube or video-assisted thoracoscopy), not intravenous
Goal	Concentrate treatment at the tumor and provoke a local anti-tumor immune response
Oncolytic Virus Trial	NCT06031636 — H101 oncolytic adenovirus + PD-1 inhibitor; status Recruiting
Photodynamic Therapy Trial	NCT04400539 (IMPALA) — intrapleural photodynamic therapy + nivolumab; Recruiting, Phase 2
Related Modality	Mesothelin-directed CAR-T cell therapy (separate page)
Regulatory Status	Investigational — not FDA-cleared for mesothelioma

Why Deliver Immunotherapy Directly Into the Chest?

Most immunotherapy for mesothelioma is given intravenously, so the drug travels through the whole body to reach the tumor. Pleural mesothelioma offers an alternative: because the tumor grows on the lining of the chest cavity, doctors can deliver treatment directly into that space through a chest tube or during keyhole thoracic surgery. The rationale for this locoregional approach is twofold. First, it concentrates the treatment where the cancer is, potentially achieving higher local exposure than a systemic dose. Second, delivering immune-activating agents into the tumor's immediate environment may provoke a stronger local immune response. This matters because, although systemic immunotherapy has improved outcomes in mesothelioma, resistance to it remains common — a problem that locoregional strategies are being designed to address. Reviews of current mesothelioma treatment now list locoregional and novel delivery approaches among the field's active future directions.

What Is Oncolytic Virotherapy?

Oncolytic viruses are viruses that have been engineered to infect and destroy cancer cells while largely sparing healthy tissue. Beyond directly killing tumor cells, they act as an immune trigger: as infected cancer cells break apart, they release signals that recruit the immune system to recognize and attack the tumor — in effect turning the cancer into its own vaccine. In pleural mesothelioma, the accessible pleural space is a natural site to deliver such a virus. A registration study is evaluating an oncolytic adenovirus (H101) combined with a PD-1 inhibitor in advanced pleural mesothelioma; its registered status is Recruiting. Combining an oncolytic virus with a checkpoint inhibitor is a deliberate pairing — the virus is intended to make an immunologically "cold" tumor more visible, and the checkpoint inhibitor then helps sustain the immune attack.

What Is Intrapleural Photodynamic Therapy Plus Immunotherapy?

A second locoregional approach combines photodynamic therapy with immunotherapy. Photodynamic therapy uses a light-sensitizing drug that accumulates in tumor tissue and is then activated by light of a specific wavelength, producing a reaction that destroys the treated cells. Delivered into the pleural space during video-assisted thoracoscopy, it treats the tumor surface directly. The IMPALA pilot trial pairs intrapleural photodynamic therapy with the anti-PD-1 antibody nivolumab, on the same logic as oncolytic virotherapy: local tumor destruction may release tumor signals that, combined with a checkpoint inhibitor, strengthen a systemic immune response. IMPALA (NCT04400539) is a Phase 2 study with a registered status of Recruiting.

How Is Treatment Delivered Into the Pleural Space?

Reliable delivery is a technical challenge in its own right, and it is an active area of preclinical research. Getting an agent to distribute evenly across the pleural surface — and doing so reproducibly — is essential for both experiments and eventual clinical use. Laboratory work has refined minimally invasive intrapleural injection techniques in animal models to achieve consistent, reproducible delivery, providing the groundwork for translating locoregional therapies into patients. In the clinic, the same pleural access used for draining fluid or performing a biopsy — a chest tube or a thoracoscope — provides the route for delivering these treatments.

How Does This Relate to CAR-T Cell Therapy?

Locoregional delivery is also central to another investigational treatment: mesothelin-directed CAR-T cell therapy, in which a patient's own immune cells are engineered to target the mesothelin protein found on mesothelioma cells and are, in some trials, infused directly into the pleural space. CAR-T is a distinct modality — it delivers living, engineered cells rather than a virus or a drug — and it is covered in detail on its own page. What the approaches share is the recognition that the pleural cavity is an accessible, high-value delivery target in mesothelioma. Readers interested in the cell-therapy approach should consult the dedicated mesothelin CAR-T page.

What Does This Mean for Patients?

For patients with pleural mesothelioma, intrapleural immunotherapy is a research frontier, not a treatment available at a typical oncology clinic. Every approach described here is investigational and accessible only through clinical trials, most at specialized centers. If you are interested, reasonable questions for your care team include whether you might be eligible for a locoregional immunotherapy trial, whether such a study is open near you, and how it would fit with the standard treatments you have already received. Setting expectations matters: these therapies aim to improve local disease control and immune activation, and their benefit in mesothelioma is still being established. Patients researching active studies can review the mesothelioma clinical trials overview.

Because mesothelioma care is expensive, families are encouraged to document treatment expenses. Compensation for these costs may be available through asbestos trust funds, U.S. Department of Veterans Affairs benefits, and legal claims against the companies responsible for the asbestos exposure that caused the disease. Families weighing their options can consult a mesothelioma law firm such as Danziger & De Llano to understand which compensation channels apply.

---

Frequently Asked Questions

What is intrapleural immunotherapy for mesothelioma?

Intrapleural immunotherapy delivers immune-activating treatment — such as an oncolytic virus or photodynamic therapy plus an anti-PD-1 drug — directly into the pleural space where pleural mesothelioma grows, rather than through a vein. The goal is to concentrate treatment at the tumor and provoke a local immune response. It is investigational, available only in clinical trials, and not FDA-cleared.

What is oncolytic virotherapy for mesothelioma?

Oncolytic virotherapy uses a virus engineered to infect and kill cancer cells while alerting the immune system to attack the tumor. In pleural mesothelioma, an oncolytic adenovirus (H101) combined with a PD-1 inhibitor is being studied in a recruiting registration trial (NCT06031636). It is investigational and not an approved treatment.

Is intrapleural immunotherapy the same as CAR-T for mesothelioma?

No. Intrapleural immunotherapy as described here refers to delivering oncolytic viruses or photodynamic therapy plus checkpoint inhibitors into the chest cavity. Mesothelin-directed CAR-T is a separate modality that delivers engineered immune cells; some CAR-T trials also use the pleural route, but the treatments are different and CAR-T is covered on its own page.

---

See Also

• Mesothelin CAR-T Therapy for Mesothelioma
• Immunotherapy for Mesothelioma
• Pleural Mesothelioma
• Mesothelioma Clinical Trials
• Mesothelioma Treatment